Bisphosphonate-associated Scleritis: A Case Report and Review
- 1 July 2005
- journal article
- case report
- Published by Southern Medical Association in Southern Medical Journal
- Vol. 98 (7), 733-735
- https://doi.org/10.1097/01.smj.0000152753.80490.9f
Abstract
An 86-year-old female was treated for osteoporosis with alendronate, an aminobisphosphonate. Six weeks after alendronate therapy began, scleritis developed in the patient's right eye. The alendronate was discontinued, and, with the administration of prednisone, the symptoms of scleritis fully resolved. Rechallenge resulted in recurrence of the symptoms. Bisphosphonates are commonly used in the management of osteoporosis and are generally safe agents. Rarely, they have been linked with ocular inflammation. This case report reviews the literature on the ocular effects of bisphosphonates and discusses a possible mechanism for the association.Keywords
This publication has 16 references indexed in Scilit:
- Bisphosphonate treatment of osteoporosisClinics in Geriatric Medicine, 2003
- Bisphosphonates and Ocular InflammationThe New England Journal of Medicine, 2003
- Scleritis and other ocular side effects associated with pamidronate disodiumAmerican Journal of Ophthalmology, 2003
- Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal OsteoporosisA Randomized Controlled TrialJama-Journal Of The American Medical Association, 1999
- Drug-Induced UveitisSurvey of Ophthalmology, 1998
- Treatment of Postmenopausal OsteoporosisThe New England Journal of Medicine, 1998
- Esophagitis Associated with the Use of AlendronateThe New England Journal of Medicine, 1996
- Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal OsteoporosisThe New England Journal of Medicine, 1995
- Pamidronate Disodium and Possible Ocular Adverse Drug ReactionsAmerican Journal of Ophthalmology, 1994
- Bisphosphonates and iritisThe Lancet, 1993